{"product_id":"jnj-bcg-matrix","title":"Johnson \u0026 Johnson (JNJ): BCG Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made BCG Matrix Analysis of Johnson \u0026amp; Johnson Business gives you a concise, research-based portfolio view of where the company is growing, funding, and pruning-covering Stars like oncology ($25.4 billion in 2025 sales), Tremfya ($5.2 billion), and MedTech cardiovascular growth, Cash Cows such as Innovative Medicine ($60.4 billion) and DARZALEX ($3.9 billion in Q4 2025), Question Marks including ICOTYDE, RYBREVANT FASPRO, Beqalzi, Hepcludex, and OTTAVA, and Dogs like Stelara (down 41.3% in FY 2025), orthopaedics, and talc. It highlights market growth, relative scale, portfolio balance, and capital-allocation priorities through June 2026, making it a practical study, research, and business-analysis reference for coursework, essays, case studies, presentations, or strategic review.\u003c\/p\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - BCG Matrix Analysis: Stars\u003c\/h2\u003e\n\n\u003cp\u003eJohnson \u0026amp; Johnson's Star businesses are the franchises combining high growth with strong market positions, supported by heavy innovation investment, expanding labels, and rising commercial momentum. In 2025 and early 2026, the clearest Stars were concentrated in oncology, immunology, and cardiovascular MedTech, with each platform showing scale, differentiation, and continued upside.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology scale and momentum\u003c\/strong\u003e stood out as the most visible Star engine. J\u0026amp;J's oncology franchise reached \u003cstrong\u003e$25.4 billion\u003c\/strong\u003e in 2025 sales, rising \u003cstrong\u003e22.1%\u003c\/strong\u003e year over year. DARZALEX generated \u003cstrong\u003e$3.9 billion\u003c\/strong\u003e in Q4 2025 sales and remained the multiple myeloma leader, while \u003cstrong\u003eCARVYKTI\u003c\/strong\u003e crossed \u003cstrong\u003e$1.0 billion\u003c\/strong\u003e in annual 2025 sales, confirming blockbuster scale in cell therapy. The January 2026 finalization of \u003cstrong\u003eHalda Therapeutics\u003c\/strong\u003e integration added \u003cstrong\u003eRIPTAC\u003c\/strong\u003e technology to the pipeline, extending the platform beyond current products. Management's \u003cstrong\u003e$50 billion oncology revenue target for 2030\u003c\/strong\u003e, alongside the raised \u003cstrong\u003e2026 sales midpoint of $100.8 billion\u003c\/strong\u003e, reinforces oncology as a core Star category with both momentum and strategic importance.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eOncology Star Indicator\u003c\/th\u003e\n\u003cth\u003e2025\/2026 Data\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFranchise sales\u003c\/td\u003e\n\u003ctd\u003e$25.4 billion in 2025\u003c\/td\u003e\n\u003ctd\u003eHigh-growth business with major scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-year growth\u003c\/td\u003e\n\u003ctd\u003e22.1%\u003c\/td\u003e\n\u003ctd\u003eStrong demand and pipeline execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX Q4 2025 sales\u003c\/td\u003e\n\u003ctd\u003e$3.9 billion\u003c\/td\u003e\n\u003ctd\u003eCategory-leading cash generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI annual sales\u003c\/td\u003e\n\u003ctd\u003eOver $1.0 billion\u003c\/td\u003e\n\u003ctd\u003eBlockbuster cell-therapy asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2030 oncology target\u003c\/td\u003e\n\u003ctd\u003e$50 billion\u003c\/td\u003e\n\u003ctd\u003eLong runway for Star expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eTremfya-driven immunology rebound\u003c\/strong\u003e is another clear Star. Tremfya grew \u003cstrong\u003e40.5%\u003c\/strong\u003e in 2025 to \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e and became a core immunology blockbuster. In May 2026, the FDA expanded its label to inhibit structural joint damage in active psoriatic arthritis, improving clinical differentiation and broadening the addressable market. J\u0026amp;J also stated that products launched within the past five years now contribute about \u003cstrong\u003e25%\u003c\/strong\u003e of total annual sales, signaling the depth of new-product momentum across the portfolio. The April 2026 launch of \u003cstrong\u003eICOTYDE\u003c\/strong\u003e adds another growth layer, while Q1 2026 sales still rose \u003cstrong\u003e9.9%\u003c\/strong\u003e to \u003cstrong\u003e$24.1 billion\u003c\/strong\u003e despite a \u003cstrong\u003e540-basis-point\u003c\/strong\u003e Stelara biosimilar headwind. The \u003cstrong\u003e7.0%\u003c\/strong\u003e full-year 2026 sales growth guide and \u003cstrong\u003e7.1%\u003c\/strong\u003e operational EPS growth guide support the view that immunology is not just defensive, but a true growth Star.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTremfya sales in 2025:\u003c\/strong\u003e $5.2 billion\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eGrowth rate:\u003c\/strong\u003e 40.5% year over year\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eNew label expansion:\u003c\/strong\u003e active psoriatic arthritis with structural joint-damage inhibition\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eRecent-launch contribution:\u003c\/strong\u003e about 25% of total annual sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e2026 guidance support:\u003c\/strong\u003e 7.0% sales growth and 7.1% operational EPS growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular MedTech breakout\u003c\/strong\u003e also fits the Star quadrant. J\u0026amp;J's MedTech cardiovascular and electrophysiology businesses delivered \u003cstrong\u003e4.6%\u003c\/strong\u003e operational growth in Q1 2026. Shockwave integration produced \u003cstrong\u003e23%\u003c\/strong\u003e operational growth in Q4 2025, while Abiomed heart pump sales rose \u003cstrong\u003e18%\u003c\/strong\u003e operationally in the same period. \u003cstrong\u003eVARIPULSE\u003c\/strong\u003e has already been used in more than \u003cstrong\u003e40,000\u003c\/strong\u003e atrial fibrillation patients globally, and \u003cstrong\u003eVARIPULSE Pro\u003c\/strong\u003e launched in Europe in April 2026. Favorable \u003cstrong\u003e12-month interim results\u003c\/strong\u003e presented at EHRA 2026 further reinforce adoption in the fast-growing pulsed-field ablation market. With \u003cstrong\u003eMedTech sales at $33.8 billion in 2025\u003c\/strong\u003e and margin expansion still targeted, the platform demonstrates both scale and growth leadership.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCardiovascular MedTech Asset\u003c\/th\u003e\n\u003cth\u003eRecent Performance\u003c\/th\u003e\n\u003cth\u003eGrowth Signal\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave\u003c\/td\u003e\n\u003ctd\u003e23% operational growth in Q4 2025\u003c\/td\u003e\n\u003ctd\u003eHigh-demand interventional platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed\u003c\/td\u003e\n\u003ctd\u003e18% operational growth in Q4 2025\u003c\/td\u003e\n\u003ctd\u003eStrong heart pump adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVARIPULSE\u003c\/td\u003e\n\u003ctd\u003e40,000+ patients treated globally\u003c\/td\u003e\n\u003ctd\u003eEarly scale in pulsed-field ablation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVARIPULSE Pro\u003c\/td\u003e\n\u003ctd\u003eLaunched in Europe in April 2026\u003c\/td\u003e\n\u003ctd\u003eGeographic expansion and new demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech sales\u003c\/td\u003e\n\u003ctd\u003e$33.8 billion in 2025\u003c\/td\u003e\n\u003ctd\u003eLarge base with further growth potential\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNew oncology platform buildout\u003c\/strong\u003e remains a capital-intensive Star-growth area. \u003cstrong\u003eRYBREVANT FASPRO\u003c\/strong\u003e moved further into growth mode after its December 2025 FDA approval in \u003cstrong\u003eEGFR-mutated NSCLC\u003c\/strong\u003e. In May 2026, \u003cstrong\u003eOrigAMI-4\u003c\/strong\u003e showed a \u003cstrong\u003e42%\u003c\/strong\u003e response rate in advanced head and neck cancer, and J\u0026amp;J submitted an \u003cstrong\u003esBLA\u003c\/strong\u003e for the indication. The company also highlighted \u003cstrong\u003eTECVAYLI plus DARZALEX FASPRO\u003c\/strong\u003e as a potential second-line standard of care in multiple myeloma. More than \u003cstrong\u003e$32 billion\u003c\/strong\u003e of combined R\u0026amp;D and strategic acquisitions in 2025 shows the level of capital deployed behind these next-wave oncology assets. AI has cut early oncology development time by \u003cstrong\u003e50%\u003c\/strong\u003e, improving the odds that these programs remain in the growth bucket rather than slipping into question-mark status.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRYBREVANT FASPRO approval:\u003c\/strong\u003e December 2025 in EGFR-mutated NSCLC\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eOrigAMI-4 response rate:\u003c\/strong\u003e 42% in advanced head and neck cancer\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003ePipeline combination:\u003c\/strong\u003e TECVAYLI plus DARZALEX FASPRO\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eInvestment intensity:\u003c\/strong\u003e more than $32 billion in combined R\u0026amp;D and strategic acquisitions in 2025\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eAI impact:\u003c\/strong\u003e 50% reduction in early oncology development time\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese Star franchises share the same BCG profile: high market growth, strong competitive positioning, and sustained capital allocation. Oncology provides the largest near-term revenue engine, immunology restores durable biologic growth, and cardiovascular MedTech expands J\u0026amp;J's higher-growth device platform with clinically differentiated products and broad adoption.\u003c\/p\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - BCG Matrix Analysis: Cash Cows\u003c\/h2\u003e\n\n\u003cp\u003eJohnson \u0026amp; Johnson's cash-cow businesses are the parts of the portfolio that combine scale, durable demand, and strong cash conversion. In 2025, that profile was most visible in Innovative Medicine and MedTech, both of which generated substantial revenue, protected margins, and supplied the free cash flow needed to fund research, launches, and shareholder returns.\u003c\/p\u003e\n\n\u003cp\u003eThese units do not require constant reinvention to keep growing. Instead, they benefit from entrenched physician adoption, repeat purchasing, global distribution, and operating leverage. That makes them classic BCG cash cows: mature, high-share businesses that convert sales into cash with relatively limited incremental investment.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCash Cow Area\u003c\/th\u003e\n\u003cth\u003e2025 \/ 2026 Performance\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Signal\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative Medicine\u003c\/td\u003e\n\u003ctd\u003e$60.4 billion 2025 sales, up 6.0% year over year; operating margins above 30%; 2026 adjusted operational EPS guidance raised to $11.55\u003c\/td\u003e\n \u003ctd\u003eLargest internal cash engine with strong conversion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX\u003c\/td\u003e\n\u003ctd\u003e$3.9 billion Q4 2025 sales; leadership in multiple myeloma; contributes to about $21 billion 2026 free cash flow expectation\u003c\/td\u003e\n \u003ctd\u003eMature blockbuster with repeat-use durability\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech\u003c\/td\u003e\n\u003ctd\u003e$33.8 billion 2025 sales, up 6.1%; Q1 2026 growth of 4.6%; about 50 bps margin improvement target\u003c\/td\u003e\n \u003ctd\u003eStable, high-volume cash generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring hospital products\u003c\/td\u003e\n\u003ctd\u003eEthicon, trauma, and related products supported by CE Mark for ETHICON 4000 Stapler and resilient trauma growth in Q1 2026\u003c\/td\u003e\n \u003ctd\u003eRepeat-purchase, low-volatility cash base\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative Medicine cash engine.\u003c\/strong\u003e Innovative Medicine generated $60.4 billion in 2025 sales, rising 6.0% year over year. Even with oncology growing faster at 22.1%, the broader segment remained Johnson \u0026amp; Johnson's largest internal cash generator. Adjusted EPS for 2025 reached $10.79, and 2026 adjusted operational EPS guidance was lifted to $11.55, reinforcing the strength of the earnings base. With operating margins above 30% after the Kenvue separation, the segment turns revenue into cash efficiently while requiring relatively limited incremental brand reinvention.\u003c\/p\u003e\n\n\u003cp\u003eThis is the kind of business that fits the cash-cow quadrant tightly: high share, mature demand, and strong monetization of established therapies. The segment's scale also gives Johnson \u0026amp; Johnson flexibility to absorb slower-performing assets while still funding pipeline investment, manufacturing upgrades, and capital returns.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e2025 sales: $60.4 billion\u003c\/li\u003e\n\u003cli\u003eYear-over-year growth: 6.0%\u003c\/li\u003e\n\u003cli\u003eAdjusted EPS: $10.79\u003c\/li\u003e\n\u003cli\u003e2026 adjusted operational EPS guidance: $11.55\u003c\/li\u003e\n \u003cli\u003eOperating margin: above 30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDARZALEX mature blockbuster.\u003c\/strong\u003e DARZALEX posted $3.9 billion in Q4 2025 sales and maintained leadership in multiple myeloma. The franchise is deeply embedded in the $60.4 billion Innovative Medicine base and helps offset the Stelara decline. Management's TECVAYLI plus DARZALEX FASPRO data also supports durability rather than signaling a need to build a brand-new market. With Johnson \u0026amp; Johnson still expecting about $21 billion of free cash flow in 2026, DARZALEX remains one of the major contributors to that engine.\u003c\/p\u003e\n\n\u003cp\u003eDARZALEX behaves like a cash cow because it combines high prescription volume, physician familiarity, and a proven commercial footprint. It does not depend on speculative demand creation; instead, it monetizes an established therapeutic category and keeps producing cash through lifecycle management and broad market penetration.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eDARZALEX Indicator\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2025 sales\u003c\/td\u003e\n\u003ctd\u003e$3.9 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic area\u003c\/td\u003e\n\u003ctd\u003eMultiple myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRole in portfolio\u003c\/td\u003e\n\u003ctd\u003eAnchors Innovative Medicine cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash flow relevance\u003c\/td\u003e\n\u003ctd\u003eSupports approximately $21 billion 2026 free cash flow\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedTech operating base.\u003c\/strong\u003e MedTech delivered $33.8 billion in 2025 sales, up 6.1%, and remains a stable cash-producing platform. Q1 2026 MedTech growth was 4.6%, while management still targets 50 basis points of operating-margin improvement through mix optimization. The 2026 plan already includes about $500 million of tariff-related costs, showing the platform is large enough to absorb macro pressure without losing its cash-generating character.\u003c\/p\u003e\n\n\u003cp\u003eThe surgery franchise restructuring was largely completed in Q4 2025, and Q1 2026 restructuring expense was only $7 million. Stable hospital procedure volumes in the U.S. and Europe continue to support this segment, making it a dependable source of operating cash rather than a high-burn growth bet.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e2025 sales: $33.8 billion\u003c\/li\u003e\n\u003cli\u003eYear-over-year growth: 6.1%\u003c\/li\u003e\n\u003cli\u003eQ1 2026 growth: 4.6%\u003c\/li\u003e\n\u003cli\u003eTargeted margin improvement: 50 basis points\u003c\/li\u003e\n \u003cli\u003eTariff-related costs in 2026 plan: about $500 million\u003c\/li\u003e\n \u003cli\u003eQ1 2026 restructuring expense: $7 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring hospital products.\u003c\/strong\u003e Ethicon, trauma, and other recurring hospital products provide the less volatile revenue base inside MedTech. Johnson \u0026amp; Johnson earned CE Mark for the ETHICON 4000 Stapler in April 2026 and reported resilient trauma growth in Q1 2026. These businesses are built on repeat purchase cycles, clinical reliability, and procurement relationships that favor long-standing suppliers.\u003c\/p\u003e\n\n\u003cp\u003eThe company is also reinforcing this base operationally. Its Global Lighthouse Network spans 132 factories, and AI-monitored digital twins are being used to protect yield and cost. U.S. operations are now powered entirely by renewable electricity contracts, which supports relationships with large hospital systems and procurement teams that increasingly scrutinize supplier resilience and sustainability credentials.\u003c\/p\u003e\n\n\u003cp\u003eThese are not speculative, high-failure-rate growth initiatives. They are high-volume, repeat-purchase businesses that throw off cash while higher-science platforms scale elsewhere in the portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRecurring Hospital Product Base\u003c\/th\u003e\n\u003cth\u003eOperational Support\u003c\/th\u003e\n\u003cth\u003eCash Cow Characteristics\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEthicon\u003c\/td\u003e\n\u003ctd\u003eCE Mark for ETHICON 4000 Stapler in April 2026\u003c\/td\u003e\n \u003ctd\u003eHigh-volume surgical demand and repeat purchasing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrauma\u003c\/td\u003e\n\u003ctd\u003eResilient Q1 2026 growth\u003c\/td\u003e\n\u003ctd\u003eStable demand tied to ongoing clinical need\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing network\u003c\/td\u003e\n\u003ctd\u003e132 factories in the Global Lighthouse Network\u003c\/td\u003e\n \u003ctd\u003eYield, cost, and supply continuity support cash conversion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy sourcing\u003c\/td\u003e\n\u003ctd\u003eU.S. operations powered by renewable electricity contracts\u003c\/td\u003e\n \u003ctd\u003eSupports large-hospital procurement relationships\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWithin the BCG Matrix, Johnson \u0026amp; Johnson's cash cows are defined by their ability to generate large, steady, and repeatable cash flows in mature markets. Innovative Medicine, DARZALEX, MedTech, and recurring hospital products all meet that standard, supplying the financial foundation that allows the company to sustain growth investments without sacrificing stability.\u003c\/p\u003e\n\u003ch2\u003eJohnson \u0026amp; Johnson - BCG Matrix Analysis: Question Marks\u003c\/h2\u003e\n\n\u003cp\u003eIn Johnson \u0026amp; Johnson's BCG portfolio, the Question Marks category captures businesses with attractive market growth but uncertain relative market share. These assets require capital, clinical execution, and commercial discipline before they can become Stars. In June 2026, several J\u0026amp;J programs fit this profile because they are newly launched, recently approved, or still waiting for broader adoption to validate their revenue potential.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eICOTYDE early launch\u003c\/strong\u003e is a clear Question Mark. The oral IL-23 receptor antagonist launched in the U.S. in April 2026 after FDA approval for moderate-to-severe plaque psoriasis. The psoriasis market is large, and J\u0026amp;J already demonstrated category strength through Tremfya, which reached $5.2 billion in 2025. Even so, ICOTYDE has no meaningful disclosed sales base yet, so market enthusiasm is still theoretical rather than proven. Its strategic value lies in extending J\u0026amp;J's once-daily oral immunology approach, but real uptake has not yet been established. The 540-basis-point Stelara headwind in Q1 2026 underscores why replacement products matter and why early launches must convert quickly into prescription momentum.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eKey 2026 Status\u003c\/th\u003e\n\u003cth\u003eBCG Interpretation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICOTYDE\u003c\/td\u003e\n\u003ctd\u003ePlaque psoriasis\u003c\/td\u003e\n\u003ctd\u003eU.S. launch in April 2026; no disclosed sales base\u003c\/td\u003e\n \u003ctd\u003eQuestion Mark with future growth potential\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRYBREVANT FASPRO\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eFDA approval in December 2025; sBLA filed in May 2026\u003c\/td\u003e\n \u003ctd\u003eQuestion Mark with possible Star pathway\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeqalzi\u003c\/td\u003e\n\u003ctd\u003eMantle cell lymphoma\u003c\/td\u003e\n\u003ctd\u003eAccelerated approval on May 13, 2026\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark with niche-market upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepcludex\u003c\/td\u003e\n\u003ctd\u003eHepatitis delta virus\u003c\/td\u003e\n\u003ctd\u003eAccelerated approval on May 22, 2026\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark with reimbursement sensitivity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTTAVA\u003c\/td\u003e\n\u003ctd\u003eSurgical robotics\u003c\/td\u003e\n\u003ctd\u003eDe Novo submission in January 2026\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark in a capital-intensive market\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRYBREVANT expansion bet\u003c\/strong\u003e also sits in Question Mark territory. RYBREVANT FASPRO secured FDA approval in December 2025 for EGFR-mutated NSCLC, and J\u0026amp;J filed an sBLA in May 2026 for head and neck squamous cell carcinoma. The OrigAMI-4 study delivered a 42% response rate, which is clinically encouraging, but not yet enough to define commercial scale. The oncology franchise benefits from faster development cycles, especially as AI has reduced early oncology development time by 50%, improving the odds of faster label expansion and better execution. Even so, as of June 2026, the asset remains a growth option rather than a proven revenue engine.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDecember 2025 FDA approval established the base indication in EGFR-mutated NSCLC.\u003c\/li\u003e\n \u003cli\u003eMay 2026 sBLA submission expanded the addressable opportunity into head and neck squamous cell carcinoma.\u003c\/li\u003e\n \u003cli\u003eOrigAMI-4 posted a 42% response rate, supporting further development.\u003c\/li\u003e\n \u003cli\u003eCommercial scale has not yet been demonstrated in disclosed financial results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBeqalzi and Hepcludex\u003c\/strong\u003e are classic Question Marks because both were only just approved in 2026. Beqalzi received accelerated FDA approval on May 13, 2026 for relapsed or refractory mantle cell lymphoma, while Hepcludex received accelerated approval on May 22, 2026 for chronic hepatitis delta virus infection. Neither asset has disclosed material sales yet, which leaves traction, payer access, and prescribing momentum unconfirmed. These are medically important niches, but they are still narrow markets relative to J\u0026amp;J's scale, and early commercialization will determine whether they remain small specialty launches or expand into meaningful contributors.\u003c\/p\u003e\n\n\u003cp\u003eJ\u0026amp;J's roughly $21 billion free cash flow outlook provides room to fund these launches, but cash strength alone does not convert a Question Mark into a Star. Adoption rates, reimbursement terms, specialist awareness, and label expansion will matter more than launch dates. In both cases, the commercial question is not whether the science is real, but whether the markets are deep enough to support durable scaling.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eApproval Date\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eCommercial Risk\u003c\/th\u003e\n\u003cth\u003ePotential Upside\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeqalzi\u003c\/td\u003e\n\u003ctd\u003eMay 13, 2026\u003c\/td\u003e\n\u003ctd\u003eRelapsed or refractory mantle cell lymphoma\u003c\/td\u003e\n \u003ctd\u003eLimited initial sales visibility\u003c\/td\u003e\n\u003ctd\u003eSpecialty oncology expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepcludex\u003c\/td\u003e\n\u003ctd\u003eMay 22, 2026\u003c\/td\u003e\n\u003ctd\u003eChronic hepatitis delta virus infection\u003c\/td\u003e\n\u003ctd\u003eNiche market and reimbursement uncertainty\u003c\/td\u003e\n \u003ctd\u003eRare-disease leadership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOTTAVA robotics development\u003c\/strong\u003e represents another Question Mark, but in a very different industry: surgical robotics. J\u0026amp;J submitted OTTAVA to the FDA for De Novo classification in January 2026. The six-arm, table-integrated system is designed with AI feedback tools to compete against Intuitive Surgical's entrenched platform, but no commercial revenue exists yet. J\u0026amp;J is not treating this as a side project; it is pairing OTTAVA with the Polyphonic digital surgery ecosystem and later Gemtrack integration to strengthen strategic optionality and platform value.\u003c\/p\u003e\n\n\u003cp\u003eThe investment level signals conviction. J\u0026amp;J committed more than $32 billion to R\u0026amp;D and strategic acquisitions in 2025, giving OTTAVA the backing needed for a long commercialization runway. But robotics is a capital-intensive category, and the key proof points are still ahead: FDA clearance, hospital adoption, installed-base growth, procedure volume, and recurring service revenue. Until those indicators appear, OTTAVA remains speculative rather than contributory.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eJanuary 2026: De Novo FDA submission for OTTAVA.\u003c\/li\u003e\n \u003cli\u003eSix-arm, table-integrated design aimed at differentiated surgical workflow.\u003c\/li\u003e\n \u003cli\u003eAI feedback tools intended to support precision and system intelligence.\u003c\/li\u003e\n \u003cli\u003ePolyphonic and Gemtrack integration strengthen the digital surgery thesis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAcross these assets, the common pattern is high strategic promise paired with incomplete commercial evidence. ICOTYDE, RYBREVANT expansion, Beqalzi, Hepcludex, and OTTAVA all operate in markets where growth potential is real, but current share, installed base, or sales scale is still too limited to classify them elsewhere in the matrix. The deciding variables are visible prescription trends, reimbursement wins, label widening, and operational execution.\u003c\/p\u003e\u003ch2\u003eJohnson \u0026amp; Johnson - BCG Matrix Analysis: Dogs\u003c\/h2\u003e\n\n\u003cp\u003eWithin Johnson \u0026amp; Johnson's June 2026 portfolio, the clearest dog characteristics are concentrated in assets that are losing share, facing structural exit decisions, or creating litigation drag without contributing to organic growth. These businesses no longer fit the company's high-science capital allocation model, and the financial data reinforce that position. While total company sales still advanced 9.9% in Q1 2026 and 6.0% in FY 2025, the weakest assets moved in the opposite direction, with declining revenue, restructuring actions, and strategic divestment signals.\u003c\/p\u003e\n\n\u003cp\u003eStelara is the most visible dog in the portfolio. FY 2025 sales fell 41.3%, and Q1 2026 still reflected a 540-basis-point headwind from biosimilar competition. The erosion is not cyclical; it is structural, tied to patent and competitive pressure that is compressing the franchise's contribution quarter by quarter. J\u0026amp;J has already shifted immunology investment toward Tremfya and ICOTYDE, which makes the replacement path explicit. Stelara remains a once-high-value asset, but its current growth profile is negative, and its strategic relevance is fading fast.\u003c\/p\u003e\n\n\u003cp\u003eThe contrast is sharper when viewed against the broader company mix. J\u0026amp;J is still posting growth at the top line, yet the portfolio is being reshaped around faster-moving, more defensible assets. Stelara's decline therefore does not indicate enterprise weakness; it signals portfolio pruning. A business unit can be historically important and still fall into the dog category once it starts destroying relative momentum and absorbing attention that could be deployed elsewhere.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePortfolio Item\u003c\/th\u003e\n\u003cth\u003eLatest Signal\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003eBCG Interpretation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelara\u003c\/td\u003e\n\u003ctd\u003eBiosimilar erosion\u003c\/td\u003e\n\u003ctd\u003eFY 2025 sales down 41.3%; Q1 2026 had a 540-basis-point headwind\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDePuy Synthes Orthopaedics\u003c\/td\u003e\n\u003ctd\u003ePlanned separation\u003c\/td\u003e\n\u003ctd\u003eSpinoff expected in 18 to 24 months; 75-basis-point growth and margin uplift targeted\u003c\/td\u003e\n \u003ctd\u003eDog-in-transition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalc legacy\u003c\/td\u003e\n\u003ctd\u003eLitigation burden\u003c\/td\u003e\n\u003ctd\u003e67,623 plaintiffs in federal MDL; $40 million California verdict; $1.5 billion Baltimore award\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-strategic surgical exits\u003c\/td\u003e\n\u003ctd\u003eWind-down and restructuring\u003c\/td\u003e\n\u003ctd\u003eQ1 2026 restructuring expense of $7 million; about $500 million in tariff-related MedTech costs absorbed in 2026 guide\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOrthopaedics at DePuy Synthes is moving toward dog status because management is preparing to separate the business within 18 to 24 months. CFO Joe Wolk said the planned spinoff should add 75 basis points to both enterprise growth and margin profile, which is a clear sign the current structure is weighing on performance. J\u0026amp;J's strategic emphasis has already shifted toward Innovative Medicine and MedTech with higher science intensity, leaving orthopaedics outside the core growth narrative. Q1 2026 trauma products remained resilient, but the broader unit still required restructuring and a new leadership setup. The planned carve-out, plus the push to bolt on Gemtrack technology, shows the business is being repositioned as a lower-priority asset rather than a growth engine.\u003c\/p\u003e\n\n\u003cp\u003eThis pattern matters because orthopaedics still generates meaningful revenue, yet the portfolio logic is changing. The company is not trying to expand the category aggressively; it is trying to simplify it, separate it, and use the proceeds and attention to fund more attractive platforms. In BCG terms, that is the behavior of a business with weak relative strategic value and limited long-term upside inside the core.\u003c\/p\u003e\n\n\u003cp\u003eThe talc legacy is another dog-like burden because it consumes cash, time, and reputation without generating operating growth. The federal MDL reached 67,623 plaintiffs in May 2026, and a California bellwether case produced a $40 million verdict in December 2025. A Baltimore jury previously awarded $1.5 billion in damages, and a New Jersey ruling allowed expert testimony in thousands of cases to proceed. J\u0026amp;J abandoned appeals of its third bankruptcy attempt and moved to direct settlement talks instead. CFO Joe Wolk said the litigation does not change long-term strategy, but the financial and managerial drag remains material.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFederal MDL plaintiff count reached 67,623 in May 2026.\u003c\/li\u003e\n \u003cli\u003eCalifornia bellwether verdict totaled $40 million in December 2025.\u003c\/li\u003e\n \u003cli\u003eBaltimore jury award reached $1.5 billion in prior proceedings.\u003c\/li\u003e\n \u003cli\u003eNew Jersey ruling kept expert testimony available in thousands of cases.\u003c\/li\u003e\n \u003cli\u003eThird bankruptcy appeal was abandoned in favor of direct settlement talks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFrom a BCG standpoint, talc is not a growth platform and not a meaningful share gainer; it is a legacy liability. Even when the company's operating businesses are expanding, this segment forces management to spend resources on legal defense, settlement strategy, and reputational containment. That makes it a classic dog: low or no growth, no strategic expansion path, and persistent cash outflow risk.\u003c\/p\u003e\n\n\u003cp\u003eNon-strategic surgical product lines also fit the dog profile because J\u0026amp;J is actively exiting them rather than scaling them. Q1 2026 restructuring expense came to $7 million, mainly tied to the exit of these lines, while the broader Surgery franchise restructuring was substantially completed in Q4 2025. The 2026 guidance already includes about $500 million of tariff-related MedTech costs, making weak-margin lines even less attractive. Capital is being redirected to VARIPULSE, OTTAVA, and the Gemtrack-enabled digital surgery stack instead. Businesses that are being wound down and replaced do not belong in the growth or cash-generation buckets.\u003c\/p\u003e\n\n\u003cp\u003eThat capital reallocation is the key signal. J\u0026amp;J is not preserving every product line for revenue continuity; it is pruning the portfolio to improve growth quality. As a result, the low-priority surgical exits are best understood as operationally useful but strategically non-core assets that are being removed from the company's future architecture.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQ1 2026 restructuring expense: $7 million.\u003c\/li\u003e\n \u003cli\u003eSurgery franchise restructuring: substantially completed in Q4 2025.\u003c\/li\u003e\n \u003cli\u003e2026 tariff-related MedTech cost burden: about $500 million.\u003c\/li\u003e\n \u003cli\u003eCapital redirected toward VARIPULSE, OTTAVA, and Gemtrack-enabled digital surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAcross these four areas, the dog pattern is consistent: Stelara is declining sharply, orthopaedics is being prepared for separation, talc is a long-running legal drain, and non-strategic surgical products are being exited. Each one either lacks growth, lacks strategic fit, or lacks both. In J\u0026amp;J's June 2026 portfolio, these are the assets that management is shrinking, separating, or settling rather than building around.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601034735765,"sku":"jnj-bcg-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/jnj-bcg-matrix.png?v=1740187349","url":"https:\/\/dcf-model.com\/pt\/products\/jnj-bcg-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}